Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Thyroid Nodule 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Solitary Fibrous Tumors 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Pruritus 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Parathyroid Neoplasms 1 Parathyroid Diseases 1 Ovarian Neoplasms 1 Opioid-Related Disorders 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Lung Neoplasms 1 Lower Urinary Tract Symptoms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Biphenotypic, Acute 1

Interventions

kang-lai-te 2 ruxolitinib 1 macimorelin 1 RC-1291 1 Pharmacogenomic Testing 1 Omacor 1 Nutrition Assessment 1 Isophane Insulin, Human 1 Eicosapentaenoic Acid 1 Docosahexaenoic Acids 1 Capsules 1 Absorptiometry, Photon 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Cachexia × Capsules × Clear all

NCT03631459 2018-08-21

A Multicenter Real World Study of Kanglaite for Cancer Cachexia

Zhejiang Kanglaite Pharmaceutical Co.Ltd

100,000 enrolled

Cancer Cachexia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡